Clinical trials: Urinary Symptoms
Overactive Bladder
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms
To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical…
- Trial name
- NCT04999657
- Testing
- Non-invasive low-frequency tibial nerve stimulator (TNS-01)
- Where
- 7 sites in China
- Volunteers
- 109 people
- Sponsor
- Medtecx Co Ltd.
Urinary Incontinence
Bladder Scan of Residual Urine With New Catheter
Male intermittent catheters (ICs) range from 340-500 mm long, with the European standard minimum length being 360 mm for a catheter without a balloon and 275 mm for one with a balloon.
- Trial name
- NCT01048541
- Testing
- Test Catheter - SpeediCath Compact Male, SpeediCath
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Coloplast A/S
Urinary Incontinence
Efficacy of rPMS for Improvement of Urinary Incontinence and Female Sexual Function
Evaluation of the repetitive pulse magnetic stimulation (rPMS) for the treatment of urinary incontinence and a female sexual satisfaction.
- Trial name
- NCT03942484
- Testing
- rPMS device
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- BTL Industries Ltd.
Neurodegenerative Diseases, Osteoarthritis
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF).
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases
- Trial name
- NCT01953523
- Testing
- Administration of autologous adipose derived SVF
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Elliot Lander
Nocturia
Long Term Safety Assessment of SER120 in Patients With Nocturia
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
- Trial name
- NCT00981682
- Testing
- SER120
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Urinary Bladder, Overactive
Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder
To assess the initial safety and clinical feasibility of neuromodulation therapy in treating patients with documented overactive bladder. The specific aim is improved urinary frequency and urgency after 12 weeks of treatment
- Trial name
- NCT00805779
- Testing
- MagPro R30
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EMKinetics, Inc
Urologic Diseases, Urinary Bladder Diseases
A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder
The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
- Conditions
- Urologic Diseases, Urinary Bladder Diseases, Urological Manifestations, Signs and Symptoms
- Trial name
- Symphony (NCT01340027)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 133 sites in Belarus, Belgium and 18 more
- Volunteers
- 1,307 people
- Sponsor
- Astellas Pharma Europe B.V.
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Overactive Bladder
Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan
The purpose of this study is to evaluate the efficacy and safety of ONO-8025 (KRP-197) in patients with overactive bladder.
- Trial name
- NCT00212706
- Testing
- ONO-8025 (KRP-197)
- Volunteers
- 400 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Vulvovaginal Atrophy, Urinary Incontinence
Combination of BTL-785F and HPM-6000UF Devices for Women's Intimate Wellness
The goal of this clinical trial is to evaluate the combined application of BTL-785F and HPM-6000UF Devices in improving quality of life in women with negative changes in the urogenital system (vulvovaginal atrophy symptoms…
- Conditions
- Vulvovaginal Atrophy, Urinary Incontinence, Sexual Dysfunction
- Trial name
- NCT06846216
- Testing
- Treatment with BTL-785F and HPM-6000UF Devices
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.
Overactive Bladder
Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron immediate release low dose or high dose tablets…
- Trial name
- NCT03475706
- Testing
- Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose
- Where
- 86 sites in United States
- Volunteers
- 438 people
- Sponsor
- Velicept Therapeutics, Inc.
Overactive Bladder (OAB)
Detrol LA In Men With Overactive Bladder.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and…
- Trial name
- NCT00282932
- Testing
- Detrol LA
- Where
- 81 sites in United States, Canada and 13 more
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder
Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women
The purpose of the trial is to investigate the efficacy of combining tolterodine and desmopressin compared with tolterodine monotherapy in the treatment of women with overactive bladder with nocturia in terms of reduction of…
- Trial name
- NCT01729819
- Testing
- Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets
- Where
- 24 sites in United States
- Volunteers
- 106 people
- Sponsor
- Ferring Pharmaceuticals
Stress Urinary Incontinence
Safety and Clinical Performance Study of the ARTUS® Artificial Urinary Sphincter (AUS)
This clinical investigation is designed as an interventional, prospective, non-randomized, open-label, single arm, multicentric and international study for obtaining CE marking.
- Trial name
- DRY (NCT04827199)
- Testing
- Artificial Urinary Sphincter implantation
- Where
- 3 sites in Czechia, Spain
- Volunteers
- 70 people
- Sponsor
- Myopowers Medical Technologies France SAS
Urinary Incontinence, Urge
Electromagnetic Stimulation for the Treatment of Urge Urinary Incontinence and Overactive Bladder
The purpose of this study is to collect data on the safety and efficacy of using an electrical field stimulation device, compared to a sham (placebo) device, to treat urinary urgency, urinary frequency and urge incontinence.
- Trial name
- ELEC STIM (NCT01464372)
- Testing
- Electrical Field Stimulation Device
- Volunteers
- 130 people
- Sponsor
- EMKinetics, Inc
Overactive Bladder
Usability Study of the FemPulse System
The objective of the study is to demonstrate that the FemPulse System can be used as indicated in the Instructions for Use (IFU), as applicable.
- Trial name
- NCT06347380
- Testing
- FemPulse System
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- FemPulse Corporation
Endometriosis Related Pain, Overactive Bladder
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
BAY1817080 is currently under clinical development to treat pain related to unexplained chronic cough or chronic cough not affected by a treatment (refractory and/or unexplained chronic cough, RUCC), or a condition where the…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04454424
- Testing
- BAY1817080, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bayer
Urinary Bladder, Overactive
Open-label Study of the Efficacy and Safety of VESIcare® in Patients With Overactive Bladder Symptoms
To evaluate the safety and efficacy of solifenacin succinate in subjects with overactive bladder symptoms (urgency, with or without urge incontinence, usually with frequency and nocturia).
- Trial name
- VOLT (NCT00463541)
- Testing
- solifenacin succinate
- Where
- 198 sites in United States
- Volunteers
- 2,225 people
- Sponsor
- Astellas Pharma Inc
Secondary Hyperoxaluria, Nephrolithiasis
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney stones.
- Conditions
- Secondary Hyperoxaluria, Nephrolithiasis, Hyperoxaluria, Kidney Stones
- Trial name
- NCT02547805
- Testing
- ALLN-177
- Where
- 22 sites in United States
- Volunteers
- 66 people
- Sponsor
- Allena Pharmaceuticals
Urinary Incontinence
Conveen Optima Urisheaths With Collecting Bags Versus Absorbents
The objective of this investigation is to asses with validated scales, the impact on the quality of life of men suffering of moderate to severe incontinence of the use of Conveen Optima urisheath in comparison with their usual…
- Trial name
- NCT01056666
- Testing
- Conveen Optima is a urisheath to be used together with a collecting bag for urine, absorbent protection
- Volunteers
- 61 people
- Sponsor
- Coloplast A/S